Eli Lilly Breaks Ground on $7B Houston Manufacturing Facility

• Eli Lilly has broken ground on a $6.5 billion, 1 million-square-foot pharmaceutical manufacturing facility in northeast Houston.
• The project is expected to create 600 permanent jobs and approximately 4,000 construction jobs.
• The facility is being developed at Generation Park, a 4,300-acre master-planned development led by McCord Development.
• The plant will use AI, machine learning, advanced data analytics and digitally integrated systems to manufacture pharmaceutical products.
• Lilly is investing $12.5 million in workforce development through San Jacinto College and another $2.5 million for scholarships.

What Eli Lilly Is Building At Generation Park

Eli Lilly and Co. has officially broken ground on a massive pharmaceutical manufacturing facility at Generation Park in northeast Houston. The 1 million-square-foot plant represents a $6.5 billion investment and will serve as an active pharmaceutical ingredient manufacturing facility. Lilly expects the plant to primarily produce Foundayo, its synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics. The facility will be built within Generation Park, a 4,300-acre master-planned development in Harris County.

 

 

What McCord Development Is Bringing To The Project

McCord Development is the master developer behind Generation Park and has been actively targeting life sciences and advanced manufacturing users for the massive Houston development. The company began pursuing life sciences tenants in 2023 before landing Lilly as a major occupant. For Generation Park, the Lilly investment represents a significant expansion of its life sciences and advanced manufacturing strategy, bringing one of the world's largest pharmaceutical companies into the development.

What The New Plant Will Bring To Houston

The project is expected to create approximately 600 permanent jobs, including positions for engineers, scientists and laboratory technicians. During construction, the development is expected to generate approximately 4,000 temporary construction jobs, creating a substantial economic impact for the northeast Houston area. The plant will also rely heavily on technology. Lilly plans to use machine learning, artificial intelligence, digitally integrated systems and advanced data analytics throughout the manufacturing operation. Texas Gov. Greg Abbott highlighted the broader economic impact of the project, saying Lilly's investment will strengthen the state's healthcare and pharmaceutical supply chain.

What Lilly Is Producing At The Facility

Foundayo will be a major focus of the facility, although Lilly plans to manufacture several other products there as well. The company said it will produce small-molecule medicines and advanced therapeutics, including oligonucleotides. Lilly describes oligonucleotides as medicines that can operate at the genetic level to reduce the production of specific proteins associated with disease. Foundayo is currently under regulatory review in more than 40 countries, with Lilly expecting a broader global rollout in 2027. The company is also studying the medicine for additional applications, including Type 2 diabetes and obstructive sleep apnea.

What The Investment Means For Houston’s Industrial Market

The Lilly project adds another major pharmaceutical manufacturing operation to Houston's growing life sciences and advanced manufacturing ecosystem. The investment also demonstrates how large industrial developments are increasingly tied to technology, specialized labor and research-driven manufacturing, rather than traditional warehouse or distribution uses. Lilly is supporting that workforce pipeline with a $12.5 million investment in San Jacinto College for training programs and a workforce center at Generation Park. The company is also contributing $2.5 million to the San Jacinto College Foundation for scholarships. With construction now underway, the $6.5 billion project is positioned to become one of the largest recent industrial and life sciences investments in the Houston region.